|
1
|
Caligaris-Cappio F and Hamblin TJ: B-cell
chronic lymphocytic leukemia: A bird of a different feather. J Clin
Oncol. 17:399–408. 1999.PubMed/NCBI
|
|
2
|
Podhorecka M, Halicka D, Klimek P, Kowal
M, Chocholska S and Dmoszynska A: Simvastatin and purine analogs
have a synergic effect on apoptosis of chronic lymphocytic leukemia
cells. Ann Hematol. 89:1115–1124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hamblin TJ and Oscier DG: Chronic
lymphocytic leukaemia: The nature of the leukaemic cell. Blood Rev.
11:119–128. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stilgenbauer S: Chronic lymphocytic
leukemia: Genetics for predicting outcome. Hematology (EHA Edur
Program). 2:185–190. 2006.
|
|
5
|
Hamblin TJ, Davis Z, Gardiner A, Oscier DG
and Stevenson FK: Unmutated Ig V(H) genes are associated with a
more aggressive form of chronic lymphocytic leukemia. Blood.
94:1848–1854. 1999.PubMed/NCBI
|
|
6
|
Inoue S, Riley J, Gant TW, Dyer MJ and
Cohen GM: Apoptosis induced by histone deacetylase inhibitors in
leukemic cells is mediated by Bim and Noxa. Leukemia. 21:1773–1782.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vogler M, Butterworth M, Majid A, Walewska
RJ, Sun XM, Dyer MJ and Cohen GM: Concurrent up-regulation of
BCL-XL and BCL2A1 induces approximately 1000-fold resistance to
ABT-737 in chronic lymphocytic leukemia. Blood. 113:4403–4413.
2009. View Article : Google Scholar
|
|
8
|
Morrison VA: Infectious complications in
patients with chronic lymphocytic leukemia: Pathogenesis, spectrum
of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma.
9:365–370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu WX, Zhou M, Cai ZB and Yang YZ:
Synthesis of new type antineoplastic drug 3, 6-dimethyl-1,
4-dihydro-s-tetrazine-1, 4-dicarboamide. Patent China: 2004
|
|
10
|
Rao GW and Hu WX: Synthesis, structure
analysis, and antitumor activity of
3,6-disubstituted-1,4-dihydro-1,2,4,5-tetrazine derivatives. Bioorg
Med Chem Lett. 16:3702–3705. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou Y, Lv Y, Xu W and Hu W: Determination
of proteasome activities with fluorogenic kinetic assays and its
application in screening proteasome inhibitor. Chi J Clin Phar
Therap. 10:1127–1133. 2008.
|
|
12
|
Qiu LN, Zhou YL, Wang ZN, Huang Q and Hu
WX: ZGDHu-1 promotes apoptosis of chronic lymphocytic leukemia
cells. Int J Oncol. 41:533–540. 2012.PubMed/NCBI
|
|
13
|
Ly JD, Grubb DR and Lawen A: The
mitochondrial membrane potential (deltapsi(m)) in apoptosis; an
update. Apoptosis. 8:115–128. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kiss T: Apoptosis and its functional
significance in molluscs. Apoptosis. 15:313–321. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Simon HU, Haj-Yehia A and Levi-Schaffer F:
Role of reactive oxygen species (ROS) in apoptosis induction.
Apoptosis. 5:415–418. 2000. View Article : Google Scholar
|
|
16
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shakir FK, Audilet D, Drake AJ III and
Shakir KM: A rapid protein determination by modification of the
Lowry procedure. Anal Biochem. 216:232–233. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
ten Cate B, Samplonius DF, Bijma T, de
Leij LF, Helfrich W and Bremer E: The histone deacetylase inhibitor
valproic acid potently augments gemtuzumab ozogamicin-induced
apoptosis in acute myeloid leukemia cells. Leukemia. 21:248–252.
2007. View Article : Google Scholar
|
|
19
|
Bouzar AB, Boxus M, Defoiche J, Berchem G,
Macallan D, Pettengell R, Willis F, Burny A, Lagneaux L, Bron D, et
al: Valproate synergizes with purine nucleoside analogues to induce
apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol.
144:41–52. 2009. View Article : Google Scholar
|
|
20
|
Newman A, Clutterbuck RD, Powles RL,
Catovsky D and Millar JL: A comparison of the effect of the
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitors simvastatin, lovastatin and pravastatin on leukaemic and
normal bone marrow progenitors. Leuk Lymphoma. 24:533–537. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dimitroulakos J, Nohynek D, Backway KL,
Hedley DW, Yeger H, Freedman MH, Minden MD and Penn LZ: Increased
sensitivity of acute myeloid leukemias to lovastatin-induced
apoptosis: A potential therapeutic approach. Blood. 93:1308–1318.
1999.PubMed/NCBI
|
|
22
|
Rao VA and Plunkett W: Activation of a
p53-mediated apoptotic pathway in quiescent lymphocytes after the
inhibition of DNA repair by fludarabine. Clin Cancer Res.
9:3204–3212. 2003.PubMed/NCBI
|
|
23
|
Cory S and Adams JM: The Bcl2 family:
Regulators of the cellular life-or-death switch. Nat Rev Cancer.
2:647–656. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sanhes L, Tang R, Delmer A, DeCaprio JA
and Ajchenbaum-Cymbalista F: Fludarabine-induced apoptosis of B
chronic lymphocytic leukemia cells includes early cleavage of
p27kip1 by caspases. Leukemia. 17:1104–1111. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Crespo M, Bosch F, Villamor N, Bellosillo
B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E and
Montserrat E: ZAP-70 expression as a surrogate for
immunoglobulin-variable-region mutations in chronic lymphocytic
leukemia. N Engl J Med. 348:1764–1775. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oscier DG, Thompsett A, Zhu D and
Stevenson FK: Differential rates of somatic hypermutation in V(H)
genes among subsets of chronic lymphocytic leukemia defined by
chromosomal abnormalities. Blood. 89:4153–4160. 1997.PubMed/NCBI
|
|
27
|
Genini D, Budihardjo I, Plunkett W, Wang
X, Carrera CJ, Cottam HB, Carson DA and Leoni LM: Nucleotide
requirements for the in vitro activation of the apoptosis
protein-activating factor-1-mediated caspase pathway. J Biol Chem.
275:29–34. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Van den Neste E, Cardoen S, Offner F and
Bontemps F: Old and new insights into the mechanisms of action of
two nucleoside analogs active in lymphoid malignancies: Fludarabine
and cladribine (Review). Int J Oncol. 27:1113–1124. 2005.PubMed/NCBI
|
|
29
|
Robak T: Therapy of chronic lymphocytic
leukemia with purine analogs and monoclonal antibodies. Transfus
Apheresis Sci. 32:33–44. 2005. View Article : Google Scholar
|
|
30
|
Kobylinska A, Bednarek J, Blonski JZ,
Hanausek M, Walaszek Z, Robak T and Kilianska ZM: In vitro
sensitivity of B-cell chronic lymphocytic leukemia to cladribine
and its combinations with mafosfamide and/or mitoxantrone. Oncol
Rep. 16:1389–1395. 2006.PubMed/NCBI
|
|
31
|
Chow KU, Nowak D, Boehrer S, Ruthardt M,
Knau A, Hoelzer D, Mitrou PS and Weidmann E: Synergistic effects of
chemotherapeutic drugs in lymphoma cells are associated with
down-regulation of inhibitor of apoptosis proteins (IAPs),
prostate-apoptosis-response-gene 4 (Par-4), death-associated
protein (Daxx) and with enforced caspase activation. Biochem
Pharmacol. 66:711–724. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nicholson DW, Ali A, Thornberry NA,
Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle
M, Lazebnik YA, et al: Identification and inhibition of the
ICE/CED-3 protease necessary for mammalian apoptosis. Nature.
376:37–43. 1995. View
Article : Google Scholar : PubMed/NCBI
|
